143 related articles for article (PubMed ID: 20451376)
1. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.
Yerramreddy TR; Milewski M; Penthala NR; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3280-3. PubMed ID: 20451376
[TBL] [Abstract][Full Text] [Related]
2. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.
Milewski M; Yerramreddy TR; Ghosh P; Crooks PA; Stinchcomb AL
J Control Release; 2010 Aug; 146(1):37-44. PubMed ID: 20678989
[TBL] [Abstract][Full Text] [Related]
3. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
Milewski M; Stinchcomb AL
Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
[TBL] [Abstract][Full Text] [Related]
4. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.
Valiveti S; Paudel KS; Hammell DC; Hamad MO; Chen J; Crooks PA; Stinchcomb AL
Pharm Res; 2005 Jun; 22(6):981-9. PubMed ID: 15948042
[TBL] [Abstract][Full Text] [Related]
5. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug.
Nalluri BN; Milligan C; Chen J; Crooks PA; Stinchcomb AL
Drug Dev Ind Pharm; 2005 Oct; 31(9):871-7. PubMed ID: 16305998
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.
Eldridge JA; Milewski M; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2014 Nov; 24(22):5212-5. PubMed ID: 25442314
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
8. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
9. Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.
Ghosh P; Lee D; Kim KB; Stinchcomb AL
Pharm Res; 2014 Jan; 31(1):148-59. PubMed ID: 23943543
[TBL] [Abstract][Full Text] [Related]
10. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs.
Valiveti S; Hammell DC; Paudel KS; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2005 Feb; 102(2):509-20. PubMed ID: 15653167
[TBL] [Abstract][Full Text] [Related]
12. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.
Ghosh P; Brogden NK; Stinchcomb AL
Mol Pharm; 2013 Jun; 10(6):2331-9. PubMed ID: 23590208
[TBL] [Abstract][Full Text] [Related]
13. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
14. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
Banks SL; Pinninti RR; Gill HS; Crooks PA; Prausnitz MR; Stinchcomb AL
Pharm Res; 2008 Jul; 25(7):1677-85. PubMed ID: 18449628
[TBL] [Abstract][Full Text] [Related]
15. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.
Pillai O; Hamad MO; Crooks PA; Stinchcomb AL
Pharm Res; 2004 Jul; 21(7):1146-52. PubMed ID: 15290853
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR
J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723
[TBL] [Abstract][Full Text] [Related]
18. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone.
Vaddi HK; Banks SL; Chen J; Hammell DC; Crooks PA; Stinchcomb AL
J Pharm Sci; 2009 Aug; 98(8):2611-25. PubMed ID: 18972573
[TBL] [Abstract][Full Text] [Related]
19. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
